KEYTRUDA® (pembrolizumab) plus LENVIMA® (lenvatinib) Combination Demonstrated Clinically Meaningful Tumor Response Rates in Unresectable Hepatocellular Carcinoma and Advanced Renal Cell Carcinoma

Analyses from KEYTRUDA Plus LENVIMA Trials to be Presented at 2020 ASCO Annual Meeting KENILWORTH, N.J. & WOODCLIFF LAKE, N.J.–(BUSINESS

Read more

Merck’s Keytruda showed increase in pathological complete response with chemotherapy versus neoadjuvant therapy chemotherapy in early-stage triple-negative breast cancer

Merck’s trial of Keytruda plus chemotherapy, followed by adjuvant Keytruda as monotherapy, which was granted Breakthrough Therapy designation (BTD) by the U.S. Food and Drug Administration (FDA) for the neoadjuvant treatment of patients with high-risk, early-stage TNBC plus chemotherapy, resulted in a statistically significant increase in pathological complete response (pCR) versus chemotherapy.

Read more